Rhabdomyosarcoma, Alveolar - 10 Studies Found
Recruiting |
: Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma :
|
Recruiting |
: A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma : Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)) : 2016-04-08 :
|
Suspended |
: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma :
|
Completed |
: Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma :
: 2010-01-22 : |
Completed |
: Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma :
: 2012-08-15 : Other: Laboratory Biomarker Analysis Correlative studies |
Completed |
: Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma :
: 2010-10-15 : |
Recruiting |
: CREATE: Cross-tumoral Phase 2 With Crizotinib :
|
Active, not recruiting |
: Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma :
|
Active, not recruiting |
: Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features :
: 2006-04-13 : Drug: Seneca Valley Virus (biological agent) Dose escalation (starting at 1 × 10^7 vp/kg), IV (in t |